- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 249/04 - Triazoles-1, 2, 3Triazoles-1, 2, 3 hydrogénés
Détention brevets de la classe C07D 249/04
Brevets de cette classe: 908
Historique des publications depuis 10 ans
|
56
|
56
|
48
|
42
|
57
|
54
|
45
|
57
|
47
|
37
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 456 |
49 |
| The Johns Hopkins University | 5723 |
18 |
| Modernatx, Inc. | 1296 |
13 |
| Yale University | 2422 |
13 |
| The Regents of the University of California | 20137 |
12 |
| Bristol-myers Squibb Company | 4850 |
9 |
| Sigilon Therapeutics, Inc. | 104 |
9 |
| Merck Sharp & Dohme LLC | 3756 |
9 |
| Siemens Medical Solutions USA, Inc. | 1511 |
8 |
| Astex Therapeutics Limited | 242 |
8 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 166 |
8 |
| The University of Queensland | 664 |
8 |
| Centre National de La Recherche Scientifique | 10576 |
7 |
| ABA Chemicals Corporation | 24 |
7 |
| Emory University | 1641 |
7 |
| The Scripps Research Institute | 1347 |
7 |
| Novartis AG | 10709 |
6 |
| Boehringer Ingelheim International GmbH | 4648 |
6 |
| Board of Regents, The University of Texas System | 5884 |
6 |
| Abbvie Inc. | 1802 |
6 |
| Autres propriétaires | 692 |